Chronic Myelogenous Leukemia Clinical Trials

12 recruitingLast updated: May 4, 2026

Chronic Myelogenous Leukemia Trials at a Glance

27 actively recruiting trials for chronic myelogenous leukemia are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Houston, Minneapolis, and New York. Lead sponsors running chronic myelogenous leukemia studies include M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, and Novartis Pharmaceuticals.

Browse chronic myelogenous leukemia trials by phase

Treatments under study

About Chronic Myelogenous Leukemia Clinical Trials

Looking for clinical trials for Chronic Myelogenous Leukemia? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Myelogenous Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Myelogenous Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 2

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals50 enrolled2 locationsNCT07354074
Recruiting

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center3,000 enrolled1 locationNCT00816114
Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Chronic Lymphocytic LeukemiaFollicular LymphomaSmall Lymphocytic Lymphoma+8 more
Masonic Cancer Center, University of Minnesota200 enrolled1 locationNCT01962636
Recruiting

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Chronic Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia
University of California, Irvine75 enrolled1 locationNCT06229860
Recruiting
Phase 4

Asciminib Roll-over Study

Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 2

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT01746836
Recruiting
Not Applicable

Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia - Chronic Phase
Centre Hospitalier Henri Duffaut - Avignon60 enrolled1 locationNCT06082804
Recruiting
Phase 1

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+15 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT03630991
Recruiting
Phase 2

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+5 more
M.D. Anderson Cancer Center90 enrolled1 locationNCT03263572
Recruiting
Phase 2

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Philadelphia Chromosome PositiveChronic Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive Chronic Myelogenous Leukemia+1 more
M.D. Anderson Cancer Center70 enrolled1 locationNCT05007873
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

LymphomaAMLLeukemia+7 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting

RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis Pharmaceuticals40 enrolled4 locationsNCT06684964
Recruiting
Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 2

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia
Medical College of Wisconsin51 enrolled4 locationsNCT04838041
Recruiting
Phase 1

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more
Florida International University65 enrolled1 locationNCT05857969